Hypoplastic MDS
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure (NCT05998408) | National Heart, Lung, and Blood Institute (NHLBI) | 2024-02-20 |
Track Hypoplastic MDS automatically
Every clearance here is in the API, with alerts when new ones post.